If we consider the new marketing authorizations for AML drugs, most of them belong to the class of targeted therapies: midostaurine and gilteritinib (anti- Fms-like tyrosine kinase 3 [FLT3)), enasidenib (anti-isocitrate deshydrogenase [IDH]2), ivosidenib (anti-IDH1), venetoclax (anti- B-cell Lymphoma 2 [BCL2]), glasdegib (Hedgehog [Hh] inhibitor). Here, IDH2 is linked to acute myeloid leukemia.